Yahoo Finance (KC) 02-Jul-11
Go Back To Yahoo Finance (KC)
Pfizer files for US approval of kidney cancer drug
NEW YORK (AP) -- Pfizer Inc. said Tuesday it filed for marketing approval of its drug candidate axitinib as a treatment for advanced renal cell carcinoma, the most common type of kidney cancer.
The company is seeking Food and Drug Administration approval based on studies that showed patients who were treated with axitinib lived longer without disease progression than patients treated with Nexavar, a cancer drug that was approved in December 2005.
On June 1, Pfizer asked European Union regulators to approve axitinib as a treatment for advanced renal cell carcinoma in patients who haven't been helped by other therapies.
The New York drugmaker said about 210,000 people are diagnosed with kidney cancer every year, and about 102,000 patients die of the disease. It said around 20 percent of patients live five years or more.
Nexavar is marketed by Onyx Pharmaceuticals Inc. and Bayer HealthCare. The drug is also approved as a treatment for liver cancer.
Pfizer shares rose 5 cents to $20.22 in morning trading Tuesday.
To View The Original Article Click Here
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
